Skip to main navigation Skip to search Skip to main content

Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy

  • Jaffer A. Ajani
  • , David M. Ota
  • , J. Milburn Jessup
  • , Fredrick C. Ames
  • , Charles McBride
  • , Arthur Boddie
  • , Bernard Levin
  • , Diane E. Jackson
  • , Mark Roh
  • , David Hohn
  • University of Texas Health Science Center at Houston
  • University of Texas MD Anderson Cancer Center

Research output: Contribution to journalArticlepeer-review

164 Scopus citations

Abstract

Patients with locoregional gastric carcinoma often die because of the low rates of curative resection and frequent appearance of distant metastases (mainly peritoneal and hepatic). To evaluate the feasibility of preoperative and postoperative chemotherapy, 25 consecutive previously untreated patients with potentially resectable locoregional gastric carcinoma received two preoperative and three postoperative courses of etoposide, 5‐fluorouracil, and cisplatin (EFP). Ninety‐eight courses (median, five courses; range, two to five courses) were administered. Six patients had major responses to EFP. Eighteen patients (72%) had curative resections, and three specimens (12%) contained only microscopic carcinoma. At a median follow‐up of 25 months, the median survival of 25 patients was 15 months (range, 4 to 32+ months). Peritoneal carcinomatosis was the most common indication of failure. One patient died of postoperative complications, but there were no deaths due to chemotherapy. EFP‐induced toxic reactions were moderate. Preoperative and postoperative chemotherapy for locoregional gastric carcinoma is feasible, and additional studies to develop regimens that could result in 5% to 10% complete pathologic responses may be warranted.

Original languageEnglish
Pages (from-to)1501-1506
Number of pages6
JournalCancer
Volume68
Issue number7
DOIs
StatePublished - Oct 1 1991

Fingerprint

Dive into the research topics of 'Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy'. Together they form a unique fingerprint.

Cite this